INOVIO Reports Interim Results Of Open-Label Phase 2 Trial Of VGX-3100 Against HPV-Associated Vulvar Dysplasia: 'reduced qualifying high-risk HPV 16/18-associated precancerous vulvar lesion area in 80% of patients (by 60% on average)'